Insider Buying: Constellation Pharmaceuticals Inc (NASDAQ:CNST) Major Shareholder Acquires $1,206,462.30 in Stock

Constellation Pharmaceuticals Inc (NASDAQ:CNST) major shareholder Group L. P. Column acquired 41,674 shares of Constellation Pharmaceuticals stock in a transaction dated Friday, March 20th. The stock was purchased at an average cost of $28.95 per share, with a total value of $1,206,462.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

CNST stock opened at $30.22 on Thursday. Constellation Pharmaceuticals Inc has a 52 week low of $6.01 and a 52 week high of $59.49. The company has a quick ratio of 17.01, a current ratio of 17.01 and a debt-to-equity ratio of 0.11. The company has a fifty day simple moving average of $33.14 and a two-hundred day simple moving average of $29.27. The firm has a market capitalization of $1.30 billion, a P/E ratio of -9.88 and a beta of 5.85.

Constellation Pharmaceuticals (NASDAQ:CNST) last released its quarterly earnings data on Tuesday, March 10th. The company reported ($0.69) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.69). As a group, analysts anticipate that Constellation Pharmaceuticals Inc will post -2.77 EPS for the current year.

A number of hedge funds have recently added to or reduced their stakes in the business. Franklin Resources Inc. bought a new position in Constellation Pharmaceuticals during the fourth quarter valued at $11,778,000. Nuveen Asset Management LLC lifted its position in Constellation Pharmaceuticals by 71.7% during the fourth quarter. Nuveen Asset Management LLC now owns 70,476 shares of the company’s stock valued at $3,320,000 after purchasing an additional 29,426 shares during the last quarter. Geode Capital Management LLC lifted its position in Constellation Pharmaceuticals by 108.9% during the fourth quarter. Geode Capital Management LLC now owns 226,327 shares of the company’s stock valued at $10,661,000 after purchasing an additional 118,009 shares during the last quarter. Perceptive Advisors LLC bought a new position in Constellation Pharmaceuticals during the fourth quarter valued at $283,000. Finally, Alliancebernstein L.P. bought a new position in Constellation Pharmaceuticals during the fourth quarter valued at $857,000. Institutional investors and hedge funds own 93.01% of the company’s stock.

A number of equities analysts recently weighed in on CNST shares. Zacks Investment Research upgraded shares of Constellation Pharmaceuticals from a “sell” rating to a “hold” rating and set a $33.00 target price for the company in a research report on Wednesday, March 11th. HC Wainwright restated a “buy” rating and set a $50.00 target price on shares of Constellation Pharmaceuticals in a research report on Tuesday, December 10th. BMO Capital Markets dropped their target price on shares of Constellation Pharmaceuticals from $42.00 to $35.00 and set a “market perform” rating for the company in a research report on Wednesday, March 11th. Robert W. Baird dropped their target price on shares of Constellation Pharmaceuticals from $65.00 to $55.00 and set an “outperform” rating for the company in a research report on Wednesday, March 11th. Finally, ValuEngine upgraded shares of Constellation Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, March 3rd. Four research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Constellation Pharmaceuticals presently has an average rating of “Buy” and an average price target of $45.00.

Constellation Pharmaceuticals Company Profile

Constellation Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors.

Featured Story: What are Institutional Investors?

Insider Buying and Selling by Quarter for Constellation Pharmaceuticals (NASDAQ:CNST)

Receive News & Ratings for Constellation Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Constellation Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.